We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy.
- Authors
Idzko, Marco; Hartl, Sylvia; Lamprecht, Bernd; Reisinger, Matthias; Löffler-Ragg, Judith; Rauter, Markus; Studnicka, Michael; Pohl, Wolfgang
- Abstract
The data show that the best therapy for symptom control and exacerbation prevention in very compliant patients (adults and adolescents) with mild asthma is regular ICS therapy plus relievers as needed. In the open-label NOVEL START study, budesonide/formoterol reliever therapy reduced exacerbation rates in patients with mild asthma more potently than SABA monotherapy, while at the same time proving equal to budesonide maintenance treatment [[40]]. Compared to twice daily budesonide maintenance therapy, as needed treatment with budesonide/formoterol has shown noninferiority for severe exacerbations in patients with mild asthma enrolled in the 52-week, double-blind, multicenter SYGMA-2 trial [[36]]. In a review O'Byrne et al. [[25]] hypothesized that the roots of this behavior and the poor outcomes of asthma treatment in many patients with even mild asthma are attributable to several paradoxes of asthma management including the change of patient autonomy across the steps of treatment.
- Subjects
PULMONARY eosinophilia; CHRONIC obstructive pulmonary disease; PHYSICIANS; MEDICAL personnel; ADRENERGIC beta agonists
- Publication
Wiener Klinische Wochenschrift, 2021, Vol 133, Issue 21/22, p1215
- ISSN
0043-5325
- Publication type
Letter
- DOI
10.1007/s00508-021-01830-1